First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes-Reference-Cited by-同舟云学术

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

Published:2023-04 Issue: Volume:183 Page:174-187
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Reck Martin^ORCID,Ciuleanu Tudor-Eliade,Cobo Manuel,Schenker Michael,Zurawski Bogdan,Menezes Juliana,Richardet Eduardo,Bennouna Jaafar,Felip Enriqueta,Juan-Vidal Oscar^ORCID,Alexandru Aurelia,Cheng Ying,Sakai Hiroshi,Paz-Ares Luis,Lu Shun,John Thomas,Sun Xiaowu^ORCID,Moisei Aniela,Taylor Fiona^ORCID,Lawrance Rachael^ORCID,Zhang Xiaoqing,Sylvester Judi^ORCID,Yuan Yong,Blum Steven I.,Penrod John R.,Carbone David P.

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. Quality of life in NSCLC survivors – a multicenter cross-sectional study;Hechtner;J Thorac Oncol,2019

2. An evidence-based determination of issues affecting quality of life and patient-reported outcomes in lung cancer: results of a survey of 660 patients;Gralla;J Thorac Oncol,2014

3. Immuno-oncology – the new paradigm of lung cancer treatment;Dawe;Curr Oncol,2020

4. The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life;Park;J Cancer Surviv,2020

5. Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms;Kluetz;Clin Cancer Res,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON);Lung Cancer;2023-12

2. Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer;Oncology;2023-09-19

3. Immunotherapy through the Lens of Non-Small Cell Lung Cancer;Cancers;2023-05-30